Patrick J Mahaffy, Clovis Oncology's President and CEO and a director of the company, just received 250,000 options from the company. The strike price of the options received was $8.39, and these expire on February 03, 2030. Mahaffy now owns at least 250,000 options on the company.
Some additional info was provided as follows:
The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Clovis Oncology makes a similar move, sign up!
Other recent filings from the company include the following:
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020